APLS | APELLIS PHARMACEUTICALS INC

CUSIP: 03753U106

0 Funds Holding

0 Total Shares

$0 Total Value

$2.8B

Market Cap

61.1

P/E Ratio

-16.4

Forward P/E

$0.36

EPS (TTM)

—

Dividend Yield

$480M

Cash

$470M

Total Debt

127M

Shares Out

$16.10

$30.91

52-Week Range

Fund / Manager Click to search	Shares	Value	% of Portfolio	Cost Basis	Est. Return
No funds currently hold this stock.

Quarter:

Fund / Manager Click to search	Action	Change	Shares After	Value	Price
2022-Q4
Viking Global Investors	SELL	EXIT	—	—	$51.71
2022-Q3
Viking Global Investors	BUY	NEW	932.4K	$64M	$61.09

6 Months Insider Sentiment

100%

Buy $0 Sell $706K

0 Buys

5 Sells

-706K Net

7 Grants

Largest

$280K Sullivan

$126K Watson

$122K Watson

Date	Insider Click to search	Role Click to search	Type	Shares	Price	Value
Jan 07, 2026	David O. Watson	General Counsel	EXERCISE	888	$14.95	$13K
Jan 05, 2026	Caroline Baumal	Chief Medical Officer	SELL	3.0K	$25.53	$77K
Jan 01, 2026	Alec Machiels	Director	GRANT	8.0K	—	—
Jan 01, 2026	Craig A Wheeler	Director	GRANT	8.0K	—	—
Jan 01, 2026	Gerald Chan	Director	GRANT	8.0K	—	—
Jan 01, 2026	Keli Walbert	Director	GRANT	8.0K	—	—
Jan 01, 2026	Paul R. Fonteyne	Director	GRANT	8.0K	—	—
Jan 01, 2026	Sinclair A. Dunlop	Director	GRANT	8.0K	—	—
Jan 01, 2026	Stephanie Monaghan O'Brien	Director	GRANT	8.0K	—	—
Dec 16, 2025	David O. Watson	General Counsel	SELL	5.0K	$24.49	$122K
Nov 17, 2025	David O. Watson	General Counsel	SELL	5.0K	$20.06	$100K
Oct 21, 2025	Timothy Eugene Sullivan	Chief Financial Officer	SELL	10.0K	$28.03	$280K
Oct 21, 2025	Timothy Eugene Sullivan	Chief Financial Officer	EXERCISE	10.0K	$10.03	$100K
Oct 16, 2025	David O. Watson	General Counsel	SELL	5.0K	$25.22	$126K

Institutional Ownership of APELLIS PHARMACEUTICALS INC